BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
BTIG has maintained its Buy rating for 89bio (NASDAQ:ETNB) and increased its price target from $30.00 to $37.00. This new target price represents a 101.25% increase from the current share price. Despite this, 89bio's shares have fallen by 2.98% over the last 24 hours.
July 03, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG has maintained its Buy rating for 89bio and raised its price target, indicating a positive outlook for the company. However, the company's shares have fallen by 2.98% over the last 24 hours.
The maintenance of the Buy rating and the increase in price target by BTIG indicates a positive outlook for 89bio. This could potentially attract investors, driving up the demand and price of the stock. However, the recent drop in share price suggests some market uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100